Latin America Breast Biopsy Needle Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Latin America Breast Biopsy Needle Market Size

• The Latin America breast biopsy needle market size was valued at USD 23.96 billion in 2024 and is expected to reach USD 43.37 billion by 2032, at a CAGR of 7.7% during the forecast period
• The market growth is largely fueled by the rising prevalence of breast cancer and increasing awareness of early detection across Latin American countries, which has prompted a greater emphasis on advanced diagnostic solutions such as breast biopsy needles. Government initiatives and cancer screening programs are further supporting early diagnosis efforts, driving demand for accurate and minimally invasive biopsy techniques
• Furthermore, technological advancements in biopsy needle design, including vacuum-assisted and core needle biopsy systems, are improving diagnostic precision and patient comfort, thus gaining preference among clinicians. These innovations, along with the growing availability of specialized diagnostic centers and trained personnel, are accelerating the adoption of breast biopsy needle solutions across Latin America, significantly boosting the industry's growth

Latin America Breast Biopsy Needle Market Analysis

• Breast biopsy needles are essential tools in diagnosing breast cancer and other abnormalities by enabling precise tissue extraction for histopathological examination. Their minimally invasive nature, combined with high diagnostic accuracy, makes them vital in both public and private healthcare settings across Latin America
• The growing demand for breast biopsy needles in Latin America is primarily fueled by increasing awareness of early breast cancer detection, rising incidence rates of breast cancer, and improved access to diagnostic imaging technologies like ultrasound and stereotactic mammography
• Brazil dominated the Latin America breast biopsy needle market with a market share of 41.3% in Latin America in 2024, driven by government-backed cancer awareness initiatives, a large patient pool, and the presence of advanced public and private diagnostic centers offering image-guided biopsy procedures
• Mexico is expected to be the fastest-growing country in the Latin America breast biopsy needle market during the forecast period of 2025 to 2032, owing to rising healthcare expenditure, expansion of diagnostic imaging services in rural and urban areas, and increased adoption of minimally invasive procedures across both public and private healthcare sectors
• The core needle segment dominated the Latin America breast biopsy needle market with a share of 46.7% in 2024, favored for its balance between accuracy and cost-efficiency. Meanwhile, the vacuum-assisted biopsy segment is projected to witness the fastest CAGR, supported by its enhanced tissue sampling capabilities and reduced need for repeat procedures

Report Scope and Latin America Breast Biopsy Needle Market Segmentation

Latin America Breast Biopsy Needle Market Trends

“Increasing Adoption of Minimally Invasive Diagnostic Technologies”

• A significant and accelerating trend in the Latin America breast biopsy needle market is the widespread adoption of minimally invasive diagnostic procedures, especially those that offer greater precision, patient comfort, and faster recovery times. This trend is reshaping how breast abnormalities are detected and diagnosed across healthcare settings in the region
  • For instance, vacuum-assisted breast biopsy (VABB) systems are gaining popularity in countries such as Brazil and Mexico for their ability to extract larger tissue samples with fewer insertions, reducing the need for follow-up procedures. These systems are increasingly preferred over open surgical biopsies due to their reduced scarring, lower cost, and improved diagnostic outcomes
• Healthcare providers across Latin America are investing in ultrasound-guided and stereotactic-guided biopsy techniques to enhance diagnostic precision. These image-guided modalities are enabling earlier detection of non-palpable lesions, improving breast cancer prognosis through timely intervention
• Furthermore, rising awareness campaigns by governments and non-governmental organizations are driving more women to undergo routine breast cancer screenings, increasing the demand for reliable biopsy needle systems. Initiatives such as Brazil’s Pink October (Outubro Rosa) campaign have significantly elevated public engagement with early breast cancer detection services
• The increased availability of public-private partnerships, expansion of diagnostic infrastructure, and the entry of global medical device companies are further propelling growth. Market players are focusing on localized training for clinicians and investing in product affordability to expand reach across urban and rural healthcare settings
• With growing emphasis on personalized medicine and early cancer detection, the demand for advanced biopsy needles—such as core needle and vacuum-assisted biopsy devices—is expected to rise steadily. This marks a pivotal shift toward less invasive, more effective diagnostic pathways in the Latin American healthcare landscape

Latin America Breast Biopsy Needle Market Dynamics

Driver

“Growing Demand Driven by Rising Cancer Awareness and Diagnostic Advancements”

• The increasing prevalence of breast cancer across Latin America, combined with growing public awareness about early detection, is a significant driver for the heightened demand for breast biopsy needle procedures
  • For instance, countries like Brazil, Mexico, and Argentina have strengthened their national screening programs and public health campaigns aimed at early breast cancer diagnosis, thereby boosting the adoption of minimally invasive diagnostic tools such as biopsy needles
• As more women participate in routine screenings and healthcare systems improve access to diagnostic imaging (such as mammography and ultrasound), the need for accurate tissue sampling is growing. Breast biopsy needles offer a less invasive, cost-effective, and reliable method for confirming malignancies, making them integral to modern breast cancer care pathways
• Furthermore, the shift towards outpatient and ambulatory diagnostic procedures is encouraging the use of core needle and vacuum-assisted biopsy devices, which reduce patient discomfort, minimize recovery time, and deliver high diagnostic yield
• The growth of private diagnostic laboratories and investment in digital pathology services also supports the rising utilization of biopsy needles across both urban and semi-urban healthcare facilities. As Latin American healthcare systems increasingly emphasize early detection, breast biopsy needles are becoming essential tools for oncologists and radiologists

Restraint/Challenge

“High Cost and Limited Infrastructure in Rural Settings”

• Despite growing demand, high procedure costs and insufficient access to advanced diagnostic infrastructure remain key challenges for broader adoption of breast biopsy needle procedures in several Latin American countries, especially in rural and underserved areas
  • For instance, vacuum-assisted biopsy systems and stereotactic imaging guidance require expensive equipment and trained personnel, which are often concentrated in urban tertiary hospitals, limiting access for populations in remote regions
• While public sector healthcare reforms are underway in many countries, economic disparities persist, creating challenges in affordability and accessibility. The reliance on imports for high-end biopsy equipment can also inflate pricing, further constraining market penetration
• To address these barriers, greater emphasis must be placed on government subsidies, partnerships with NGOs, and the development of cost-effective, portable biopsy solutions. In addition, investment in training programs and mobile diagnostic clinics can significantly enhance service delivery in low-resource settings
• Tackling infrastructure and affordability gaps will be crucial to ensuring equitable access to early breast cancer diagnosis across Latin America, thereby supporting long-term market growth for biopsy needle systems

Latin America Breast Biopsy Needle Market Scope

The market is segmented on the basis of needle type, ergonomic design, procedure, usability, application, end user, and distribution channel.

• By Needle Type

On the basis of needle type, the Latin America breast biopsy needle market is segmented into fine-needle aspiration and core needle. The core needle segment dominated the market with the largest revenue share of 46.7% in 2024, driven by its higher tissue yield and greater diagnostic accuracy.

The fine-needle aspiration segment is expected to grow at the fastest CAGR of 8.9% from 2025 to 2032, owing to its affordability and minimally invasive nature.

• By Ergonomic

On the basis of ergonomic design, the Latin America breast biopsy needle market is segmented into sharp, blunt, Quincke, Chiba, Franseen, and others. The sharp segment held the largest revenue share of 28.4% in 2024, owing to widespread preference for traditional sharp-tip needles in diagnostic procedures.

The Franseen segment is projected to register the fastest CAGR of 9.6% over the forecast period, due to enhanced sampling efficacy and patient comfort.

• By Procedure

On the basis of procedure, the Latin America breast biopsy needle market is segmented into fine-needle aspiration biopsy, core needle biopsy, vacuum-assisted biopsy, and image-guided biopsy. The image-guided biopsy segment accounted for the highest revenue share of 39.7% in 2024, fueled by demand for precision-guided diagnostics.

The vacuum-assisted biopsy segment is expected to expand at the highest CAGR of 10.2% through 2032, due to its less invasive, efficient, and accurate tissue sampling.

• By Usability

On the basis of usability, the Latin America breast biopsy needle market is segmented into disposable and reusable. The disposable segment dominated with a market share of 72.5% in 2024, attributed to safety concerns and widespread infection control practices.

The reusable segment is projected to grow at a highest CAGR of 7.5% during the forecast period, driven by efforts to reduce medical waste and improve cost efficiency.

• By Application

On the basis of application, the Latin America breast biopsy needle market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The early cancer screening segment held the largest share of 47.9% in 2024, owing to rising awareness and government initiatives.

The treatment monitoring segment is anticipated to grow at a highest CAGR of 8.8%, due to increasing reliance on biopsy tools to evaluate therapy effectiveness.

• By End User

On the basis of end user, the Latin America breast biopsy needle market is segmented into hospitals, diagnostic centres, biopsy labs, ambulatory surgical centres, academic and research organizations, and others. The hospitals segment led the market with a 58.6% share in 2024, due to availability of specialized facilities and skilled personnel.

The ambulatory surgical centres segment is projected to witness the highest CAGR of 9.1% through 2032, supported by the rising demand for cost-effective outpatient procedures.

• By Distribution Channel

On the basis of distribution channel, the Latin America breast biopsy needle market is segmented into direct tender and retail sales.

The direct tender segment held the dominant market share of 66.8% in 2024, benefiting from large-volume institutional purchases and centralized procurement systems.

The retail sales segment is forecasted to grow at a CAGR of 9.4%, driven by expanding access to medical supplies through e-commerce and third-party distributors.

Latin America Breast Biopsy Needle Market Regional Analysis

• Latin America accounted for a significant revenue share of 22.6% in the global breast biopsy needle market in 2024, driven by increasing breast cancer incidence, expanding healthcare infrastructure, and growing awareness regarding early detection across the region
• Countries in Latin America are increasingly adopting advanced diagnostic tools, and breast biopsy needles are becoming essential components of early cancer screening programs, particularly in urban and semi-urban regions
• Government initiatives and NGO-led screening campaigns are further enhancing market penetration of core needle and vacuum-assisted biopsy technologies in the region

Brazil Latin America Breast Biopsy Needle Market Insight

Brazil dominated the Latin America breast biopsy needle market with the largest revenue share of 41.3% in 2024, fueled by a high prevalence of breast cancer and strong public health programs such as the “Pink October” campaign. The availability of advanced biopsy systems in both public and private healthcare settings is also contributing to market expansion. Brazil’s strong diagnostic laboratory network and growing demand for minimally invasive procedures further support growth.

Mexico Latin America Breast Biopsy Needle Market Insight

The Mexico breast biopsy needle market is expected to grow at a CAGR of 8.9% from 2025 to 2032, driven by rising investments in diagnostic imaging centers, increased healthcare access, and rising awareness among women regarding preventive health. Cross-border medical tourism and the presence of large private hospital chains are also facilitating the adoption of modern biopsy technologies, including image-guided and vacuum-assisted methods.

Argentina Latin America Breast Biopsy Needle Market Insight

Argentina is anticipated to witness a steady CAGR of 7.6% during the forecast period, supported by national cancer control initiatives and improved public healthcare expenditure. Rising patient awareness, growing training programs for minimally invasive diagnostics, and partnerships with international medical device companies are accelerating the uptake of high-precision biopsy tools in major cities like Buenos Aires, Córdoba, and Rosario.

Latin America Breast Biopsy Needle Market Share

The Latin America breast biopsy needle industry is primarily led by well-established companies, including:

• Medax SRL (Italy)
• Cook (U.S.)
• BD (U.S.)
• Medtronic (Ireland)
• Hologic, Inc. (U.S.)
• Leica Biosystems Nussloch GmbH (Germany)
• Devicor Medical Products Inc. (U.S.)
• Danaher corporation (U.S.)
• Argon Medical Devices (U.S.)

Latest Developments in Latin America Breast Biopsy Needle Market

• In May 2023, Argon Medical Devices introduced the SuperCore Advantage Semi-Automatic Biopsy Instrument, a new addition to the biopsy needle market. This innovative device aims to improve biopsy procedures with enhanced efficiency and precision, potentially offering healthcare professionals advanced tools to enhance diagnostic accuracy and patient outcomes
• In April 2021, AprioMed extended its collaboration with Cenova, aiming to bolster its foothold in the South American market. This strategic alliance may enhance their presence and offerings in the breast biopsy needle market, potentially enabling AprioMed to capitalize on emerging opportunities and meet the region's healthcare needs more effectively
• In February 2021, Hologic Inc's acquisition of biotheranostics marked their entry into the expanding oncology market, including breast cancer. This strategic move enhances their network and capabilities in cancer diagnostics, potentially benefiting their offerings in the breast biopsy needle market through increased innovation and market presence

SKU-64258